Rapid Readouts: Efficacy of Novel Targeted Therapies Post-MURANO Study

The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.

The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Oral azacitidine and cedazuridine met the end point of total cycle azacitidine exposure vs subcutaneous azacitidine in MDS or CMML.

Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.

The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.

The NMPA has approved of pirtobrutinib in treatment-naive and previously treated CLL/SLL.